Adiponectin

What is Adiponectin?

Adiponectin is a 244-amino-acid peptide hormone secreted almost exclusively by adipocytes, making it quantitatively the most abundant adipose-derived protein in human serum (typically 3–30 μg/mL — orders of magnitude higher than most circulating hormones). Its defining paradox: despite being made by fat cells, circulating levels decline as adiposity rises. Lean, metabolically healthy individuals have the highest levels; obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease are consistently hypoadiponectinemic states. Adiponectin circulates as three structurally distinct oligomers — trimers, hexamers, and high-molecular-weight (HMW) multimers of ~12–18 subunits — with the HMW form considered the most bioactive. It acts through two receptors (AdipoR1, dominant in skeletal muscle; AdipoR2, dominant in liver) to activate AMPK and PPAR-α signaling, enhancing insulin sensitivity, fatty acid oxidation, and anti-inflammatory programs. Adiponectin is not available as a therapeutic — its large multimeric structure has frustrated drug development — and the practical clinical path is through small-molecule AdipoR agonists (AdipoRon being the lead compound), none of which are yet approved.

What Adiponectin Is Investigated For

Adiponectin is one of the most thoroughly characterized endogenous peptides in metabolic medicine and one of the least useful to administer. As a biomarker it is exceptional: low levels consistently and independently predict incident type 2 diabetes, myocardial infarction, and metabolic syndrome in large prospective cohorts. As a therapeutic it has not translated. The molecule's bioactivity depends on its high-molecular-weight multimeric structure (trimers assembling into hexamers assembling into 18-mers stabilized by disulfide bonds), which is not something you can simply inject as a synthetic peptide and expect to recapitulate. The pragmatic drug-discovery response has been to identify small-molecule agonists at the adiponectin receptors (AdipoR1 and AdipoR2) — AdipoRon, reported by the Kadowaki group in Nature in 2013, is the lead example and is orally active in rodents. No AdipoR-targeted therapeutic has yet reached approval. Readers arriving at this page looking for 'adiponectin therapy' should understand that the honest answer is: raising your endogenous adiponectin through weight loss, exercise, and (in some populations) thiazolidinediones is the only current practical path.

History & Discovery

Adiponectin has one of the most unusual origin stories in modern endocrinology: it was discovered independently, more or less simultaneously, by four different groups using four different approaches between 1995 and 1996, and then spent several years being referred to by four different names before the field settled on a unified nomenclature. Philipp Scherer at Harvard, working with Harvey Lodish's group, used a cDNA subtractive library enriched for messages upregulated during adipocyte differentiation in the 3T3-L1 mouse adipocyte model. The most abundant hit was a novel secreted protein with a C-terminal globular domain resembling the complement component C1q. They named it Acrp30 — adipocyte complement-related protein of 30 kDa — and published in the Journal of Biological Chemistry in November 1995. Independently, Kazuhisa Maeda and Yuji Matsuzawa's group at Osaka used a direct cDNA-sequencing approach on human adipose tissue and identified the most abundant transcript, which they named apM1 ('adipose most abundant gene transcript 1'), published in BBRC in 1996. A third group, Nakano and colleagues, arrived at the same molecule through a completely different route — purifying a 28-kDa gelatin-binding protein from human plasma — and named it GBP-28, published in the Journal of Biochemistry in 1996. A fourth lineage, Hu/Liang/Spiegelman at the Dana-Farber, identified a PPAR-γ-responsive adipocyte transcript they called AdipoQ in 1996. All four groups had found the same molecule. The name 'adiponectin' was coined by the Matsuzawa group around 1999 as they moved from the apM1 nomenclature to a functional name, and the field converged on it over the next several years. The landmark finding that redirected the field was Arita et al. 1999 — the paradoxical demonstration that despite being made by adipose tissue, adiponectin falls with obesity. This inverted the expected adipokine pattern (leptin rises with fat mass) and opened the therapeutic-target hypothesis that would drive the next two decades of work. The mechanistic core was filled in rapidly. Yamauchi, Kadowaki and colleagues in 2001 showed that recombinant adiponectin reverses insulin resistance in lipoatrophic and obese mouse models. Berg and Scherer in 2001 showed that adiponectin enhances hepatic insulin action. Yamauchi's group in 2002 established AMPK activation as the dominant mechanism in muscle and liver. Pajvani and colleagues in 2003 worked out the disulfide-stabilized oligomeric structure and its functional consequences. And in June 2003, Yamauchi's group cloned AdipoR1 and AdipoR2, the seven-transmembrane receptors that mediate adiponectin's antidiabetic effects, in a paper in Nature. The epidemiological phase followed — Pischon et al. 2004 JAMA showed that high adiponectin predicts lower MI risk in apparently healthy men — cementing the molecule as both a biomarker and a drug target. The direct therapeutic program has not delivered a drug, for reasons that trace back to the structural work: adiponectin's bioactivity depends on its 12-to-18-subunit HMW oligomeric state, which is not trivially reproduced with recombinant technology in a form that survives administration. The field's forward push, spearheaded by the Kadowaki group, shifted to small-molecule AdipoR agonists — AdipoRon, reported in Nature in 2013, is the lead example. No AdipoR-targeted therapeutic has reached approval as of 2026, but the pipeline is active and includes monoclonal-antibody approaches that mimic adiponectin binding to AdipoR.

How It Works

Adiponectin is a hormone that fat cells make to tell the rest of the body 'we are well-fed but not overloaded — keep insulin working and burn fat efficiently.' Lean people make a lot of it. Paradoxically, the more fat a person carries (especially visceral fat), the less adiponectin they make, which is part of why obesity causes insulin resistance. Adiponectin works through two receptors — AdipoR1 in muscle and AdipoR2 in liver — to activate an energy-sensing enzyme called AMPK, which improves how muscle uses glucose and how the liver handles fat. The problem for drug development is that adiponectin only works well when it assembles into large multi-subunit complexes, which can't be easily reproduced as an injectable drug. So the current push is toward small-molecule pills that activate the adiponectin receptors directly.

Adiponectin is a 244-amino-acid peptide with a signal sequence, a short N-terminal hypervariable region, a collagenous domain of 22 G-X-Y repeats, and a C-terminal globular domain with structural homology to C1q and TNF-family proteins. It assembles obligately into trimers via the globular domain, and trimers further assemble into hexamers (LMW), and hexamers into 12-to-18-subunit HMW complexes stabilized by disulfide bonds through a conserved Cys-39 in the N-terminal variable region. The oligomeric state is functionally critical: HMW adiponectin carries most of the metabolic bioactivity, while trimers and a proteolytically cleaved globular fragment (gAd) have distinct, less potent activities. Adiponectin acts through two seven-transmembrane receptors with inverted topology relative to classical GPCRs: AdipoR1, highly expressed in skeletal muscle, preferentially activates AMP-activated protein kinase (AMPK) and downstream acetyl-CoA carboxylase (ACC) phosphorylation, driving increased fatty acid oxidation and GLUT4-mediated glucose uptake. AdipoR2, highly expressed in liver, preferentially activates PPAR-α signaling, enhancing hepatic fatty acid oxidation and suppressing gluconeogenesis. The Iwabu 2010 Nature paper established that AdipoR1-mediated AMPK activation proceeds through an APPL1-dependent calcium influx, activating CaMKKβ, AMPK, and SIRT1, which together drive PGC-1α deacetylation and mitochondrial biogenesis in skeletal muscle — providing a molecular basis for adiponectin's effects on muscle oxidative capacity. A third binding partner, T-cadherin, is essential for adiponectin's cardiovascular protective effects but is not a classical signaling receptor. In addition to the AMPK/PPAR-α axis, adiponectin suppresses hepatic gluconeogenesis (Berg/Scherer 2001), inhibits TNF-α-induced NF-κB signaling in endothelium, increases ceramidase activity (which degrades pro-apoptotic ceramides), and activates hypothalamic AMPK to modestly increase food intake and decrease energy expenditure during fasting (Kubota 2007 — a finding that complicated the early simple 'adiponectin = good' narrative). The net systemic effect in non-HF states is insulin sensitization, anti-atherogenesis, anti-inflammation, and improved lipid metabolism.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Adiponectin:

• 01Whether pharmacologic activation of AdipoR1/R2 (via AdipoRon or successor compounds) translates to cardiovascular and metabolic benefit in humans — the rodent proof-of-concept has not been followed by a late-stage human trial.
• 02Whether the HMW-to-total adiponectin ratio is a clinically actionable endpoint distinct from total adiponectin, or whether it is simply a noisier biomarker of the same underlying signal.
• 03The 'adiponectin paradox' in established heart failure — high levels predict worse outcomes — and whether this reflects reverse causality, a true pathologic role in HF, or a compensatory signal.
• 04Whether the Mendelian randomization evidence supports a causal role for adiponectin in metabolic disease or whether the association is largely confounded by adiposity.
• 05The precise receptor pharmacology at AdipoR1 versus AdipoR2 and whether selective agonists (R1-biased or R2-biased) would offer tissue-specific benefit.
• 06The role of T-cadherin as an adiponectin-binding partner in cardiovascular protection, and whether this pathway is pharmacologically tractable.
• 07Whether monoclonal-antibody agonists of AdipoR (a more recent development path) can overcome the pharmacokinetic and delivery challenges of small-molecule AdipoR agonists.
• 08Whether lifestyle interventions that raise adiponectin (weight loss, exercise, Mediterranean diet) produce their metabolic benefits in part through adiponectin elevation, or whether adiponectin is a passive marker of those interventions.

Forms & Administration

Adiponectin is not available as an approved therapeutic product. Research-grade recombinant adiponectin (both full-length and globular fragment forms) is used in preclinical laboratory work, typically administered parenterally in rodent models, but it is not a legitimate clinical option and should not be understood as a peptide-therapy category. The practical paths to raising circulating endogenous adiponectin are (1) fat-mass reduction via diet and exercise — adiponectin rises as adiposity falls; (2) thiazolidinedione therapy (pioglitazone, rosiglitazone) in appropriate diabetic populations, which substantially increases HMW adiponectin via PPAR-γ activation; and (3) specific dietary and lifestyle patterns (Mediterranean-pattern intake, omega-3-rich fish, moderate alcohol, adequate sleep, aerobic exercise) that have been associated with higher adiponectin levels in observational work. Small-molecule AdipoR agonists (AdipoRon and analogues) are investigational and not available for clinical use.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions